Truveta Strengthens Regulatory-Grade Evidence Business With Pharmacoepidemiology Leader Hire

New updates have been reported about Truveta.

Truveta has appointed pharmacoepidemiology expert John D. Seeger, PharmD, DrPH, FISPE, to lead its Truveta Evidence Services unit, signaling a strategic push to deepen its role as a provider of regulatory-grade real-world evidence for life sciences clients. Seeger, who has more than 30 years of experience designing and overseeing large-scale observational studies for regulatory and safety decisions, is expected to enhance Truveta’s capacity to generate fit-for-purpose evidence that meets increasingly demanding standards from regulators and global health authorities.

Under Seeger’s leadership, Truveta plans to accelerate delivery of high-quality evidence used in drug safety, comparative effectiveness, and public health policy, leveraging its health system–owned data and advanced analytics platform to support faster, more robust regulatory submissions and post-market surveillance. CEO Terry Myerson framed the hire as core to Truveta’s strategy to “save lives with data,” while Chief Medical Officer and co-founder Ryan Ahern highlighted that Seeger’s background at RTI-HS, Optum, and Harvard strengthens the company’s credibility with regulators and life science customers, potentially expanding its addressable market across pharma, biotech, government, and academic research.

Seeger said Truveta’s combination of de-identified patient-level data, scientific rigor, and analytics positions it to move beyond traditional “check-the-box” safety studies toward more impactful, decision-grade research. He joins alongside President and Chief Scientific Officer Johnathan Lancaster as Truveta builds out a senior scientific leadership bench aimed at scaling its evidence services business. Strategically, this appointment supports Truveta’s ambitions to be a preferred real-world intelligence partner to U.S. and global life sciences companies, embedding its data and AI-driven insights more deeply into clinical development, regulatory strategy, and post-approval evidence generation.